Retinal cases & brief reports · 2025
DOCETAXEL-INDUCED PIGMENTARY MACULOPATHY.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Skrehot Henry C, Alsoudi Amer, Chang Emmanuel Y, Holz Eric R
Аннотация
PURPOSE: The objective of this study was to report a case of bilateral docetaxel-induced pigmentary maculopathy in an adult.
METHODS: A 79-year-old man with prostate cancer was treated with docetaxel and subsequently developed progressively worsening blurred vision. Before initiation of docetaxel therapy, his best corrected visual acuity was 20/20 in the right and left eye. He presented to clinic 5 months after the initiation of docetaxel therapy with best corrected visual acuity of 20/70 and 20/40 -2 in the right and left eye, respectively. Fundoscopic examination was notable for bilateral focal central areas of macular hyperpigmentation. Toxic maculopathy secondary to docetaxel was suspected, and the recommendation to discontinue docetaxel was made to the oncologist.
RESULTS: Five months after discontinuation of docetaxel, the patient's best corrected visual acuity improved to 20/40 -2 in the right and left eye. Fundoscopic examination was stable in both eyes.
CONCLUSION: Bilateral pigmentary maculopathy presenting as focal areas of macular hyperpigmentation developed after the initiation of docetaxel in an adult with no previous ocular history. Prompt diagnosis and cessation of docetaxel resulted in stable disease.
METHODS: A 79-year-old man with prostate cancer was treated with docetaxel and subsequently developed progressively worsening blurred vision. Before initiation of docetaxel therapy, his best corrected visual acuity was 20/20 in the right and left eye. He presented to clinic 5 months after the initiation of docetaxel therapy with best corrected visual acuity of 20/70 and 20/40 -2 in the right and left eye, respectively. Fundoscopic examination was notable for bilateral focal central areas of macular hyperpigmentation. Toxic maculopathy secondary to docetaxel was suspected, and the recommendation to discontinue docetaxel was made to the oncologist.
RESULTS: Five months after discontinuation of docetaxel, the patient's best corrected visual acuity improved to 20/40 -2 in the right and left eye. Fundoscopic examination was stable in both eyes.
CONCLUSION: Bilateral pigmentary maculopathy presenting as focal areas of macular hyperpigmentation developed after the initiation of docetaxel in an adult with no previous ocular history. Prompt diagnosis and cessation of docetaxel resulted in stable disease.